Connexin (Gap Junction Protein) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Connexin (Gap Junction Protein) – Pipeline Review, H2 2016’, provides in depth analysis on Connexin (Gap Junction Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Connexin (Gap Junction Protein) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connexin (Gap Junction Protein) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Connexin (Gap Junction Protein)

The report reviews Connexin (Gap Junction Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Connexin (Gap Junction Protein) targeted therapeutics and enlists all their major and minor projects

The report assesses Connexin (Gap Junction Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Connexin (Gap Junction Protein) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Connexin (Gap Junction Protein)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Connexin (Gap Junction Protein) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Theranexus SAS

Vichem Chemie Research Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Connexin (Gap Junction Protein) Overview 6

Therapeutics Development 7

Connexin (Gap Junction Protein) - Products under Development by Stage of Development 7

Connexin (Gap Junction Protein) - Products under Development by Therapy Area 8

Connexin (Gap Junction Protein) - Products under Development by Indication 9

Connexin (Gap Junction Protein) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Connexin (Gap Junction Protein) - Products under Development by Companies 12

Connexin (Gap Junction Protein) - Products under Development by Universities/Institutes 14

Connexin (Gap Junction Protein) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Connexin (Gap Junction Protein) - Companies Involved in Therapeutics Development 23

Theranexus SAS 23

Vichem Chemie Research Ltd. 24

Connexin (Gap Junction Protein) - Drug Profiles 25

(flecainide acetate + modafinil) - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

CODA-001 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

JM-2 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

THN-01 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

VID-45110 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Connexin (Gap Junction Protein) - Dormant Projects 33

Connexin (Gap Junction Protein) - Discontinued Products 35

Connexin (Gap Junction Protein) - Featured News & Press Releases 36

May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness 36

Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep 37

Oct 19, 2015: Theranexus: Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders, in partnership with the French Armed Forces Biomedical Research Institute (IRBA) 37

Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies 38

Jan 09, 2013: CoDa Therapeutics Announces Positive Results From Phase IIb Study Of Nexagon In Chronic Venous Leg Ulcers 39

May 25, 2010: CoDa Therapeutics Achieves Positive Results From Phase II Efficacy Study Of NEXAGON In Chronic Venous Leg Ulcers 39

May 11, 2009: CoDa Therapeutics Receives Orphan Drug Designation For Nexagon For The Treatment Of Persistent Corneal Epithelial Defects 40

Appendix 42

Methodology 42

Coverage 42

Secondary Research 42

Primary Research 42

Expert Panel Validation 42

Contact Us 42

Disclaimer 43

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Theranexus SAS, H2 2016 23

Pipeline by Vichem Chemie Research Ltd., H2 2016 24

Dormant Projects, H2 2016 33

Dormant Projects (Contd..1), H2 2016 34

Discontinued Products, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Assessment by Monotherapy/Combination Products, H2 2016 16

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports